Epigenetic Reprogramming and Cellular Rejuvenation

Aging is partly driven by epigenetic noise. Partial and cyclic Yamanaka factor reprogramming has restored vision in aged mice with glaucoma and extended mouse lifespan by 25 percent in Altos Labs experiments. Altos Labs, founded with a billion-dollar funding round, is targeting Phase 1 human trials by 2027. If successful, partial reprogramming could represent the most fundamental anti-aging technology ever developed.